Search results
Results From The WOW.Com Content Network
Cadila was founded in 1952 by Ramanbhai Patel (1925–2001), formerly a lecturer in the L.M. College of Pharmacy, and his business partner Indravadan Modi. [8]In 1995, the Patel and Modi families split; the Modi family's share was moved into a new company called Cadila Pharmaceuticals, and Cadila Healthcare became the Patel family's holding company.
Cadila Pharmaceuticals is an Indian multinational pharmaceutical company based in Ahmedabad. The company's operations focus on manufacturing products ranging from active pharmaceutical intermediates , finished formulations , food supplements, biotechnology products and pharmaceutical machinery.
Cadila Healthcare began phase II trials of the vaccine candidate from 6 August 2021 with over 1,000 volunteers as part of the adaptive Phase I/II multi-centric, dose escalation, randomised, double-blind placebo controlled method. [10] [11] [12] The company reported that phase II trials were completed by November 2020. [13] [14]
India's Zydus Cadila has sought regulatory approval for clinical trials of its antibody cocktail to treat mild COVID-19, as the country grapples with a shortage of medicines and vaccines needed to ...
India's Zydus Cadila plans to complete late-stage trials for its novel coronavirus vaccine candidate by February or March and could produce up to 100 million doses a year initially if it is ...
Zydus, listed as Cadila Healthcare, joins other Indian pharmaceutical companies Cipla Ltd, Jubilant Sciences Ltd and privately held Hetero Labs Ltd in signing non-exclusive pacts with Gilead for ...
Patel, in 1976 after graduation, joined the firm Cadila Healthcare, which was founded by his father in 1952 to make vitamins. [6] In 1995, Cadila Laboratories and Cadila Healthcare split under Zydus Group. Zydus's word is taken from the Greek god, Zeus. The letter D was added to Zeus, and it became Zydus.
India's Cadila Healthcare has started producing its potential COVID-19 vaccine for which it will seek emergency use authorisation in May or June, its managing director told Reuters, with an aim to ...